Genetic Technologies Stock

Genetic Technologies Enterprise Value

The Enterprise Value (EV) of Genetic Technologies (GTG.AX) as of Aug 15, 2026 is 51.93 M AUD. In the previous year, Enterprise Value (EV) was 44.76 M AUD — a change of 16.02% (higher).

Enterprise Value

51.93 MAUD

YoY

16.02%

Last updated:

Enterprise Value (EV) of Genetic Technologies is 2026 51.93 M AUD. Enterprise Value (EV) of Genetic Technologies was 2025 44.76 M AUD. It decreases by 16.02% higher compared to the previous year.
Access this data via the Eulerpool API

Genetic Technologies Stock analysis

What does Genetic Technologies do? Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Technologies stock

Enterprise Value (EV) of Genetic Technologies is 51.93 M AUD in 2026.

Enterprise Value (EV) of Genetic Technologies changed from 44.76 M AUD to 51.93 M AUD, representing a 16.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Genetic Technologies since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s AUD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' AUD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Genetic Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Genetic Technologies

All Key Metrics — Genetic Technologies